Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: Results of a 12-week randomised, double-blind, controlled study

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 323-329

  Sieper, J ^a   Klopsch, T ^b   Richter, M ^c   Kapelle, A ^d   Rudwaleit, M ^a   Schwank, S ^e   Regourd, E ^e   May, M ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Rheumatology Practice   (Germany)

^c Rheumatology Practice   (Germany)

^d Abteilung Rheumatologie ^*  (Germany)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PROTON PUMP INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; BLISTER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPNEA; EPIGASTRIC DISCOMFORT; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL TOXICITY; HEADACHE; HEARING LOSS; HEMORRHOID HEMORRHAGE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH DISCOMFORT; TACHYCARDIA; TONGUE SWELLING; TOOTH PAIN; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PYRAZOLES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; SULFONAMIDES; TREATMENT OUTCOME;

EID: 39549108490     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.075309     Document Type: Article

References (22)

1. Amor B, Dougados M, Listrat V, Menkes C, Roux H, Benhamou C, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-15.
2. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
3. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
4. Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
5. Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27:1876-83.
6. Goldstein J, Silverstein F, Agrawal N, Hubbard R, Kaiser J, Maurath C, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
7. Brophy JM. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005;4:1005-15.
8. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66.
9. Arber N, Eagle C, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
10. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
11. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
12. Dougados M, Behier J, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
13. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious in treating the signs and symptoms of ankylosing spondylitis. Ann Rheum Dis 2005;64(Suppl 3):338.
14. Garrett S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
15. Calin A, Garrett S, Whitelock H, Kennedy L, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
16. Jenkinson T, Mallorie P, Whitelock H, Kennedy L, Garrett S, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
17. van der Heijde D, Baraf H, Ramos-Remus C, Calin A, Weaver A, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15.
18. Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005;64:1563- 7.
19. Emery P, Zeidler H, Kvien T, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
20. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith J, Geis G. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-18.
21. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002;61(Suppl 3):iii40-50.
22. Wanders A, Heijde D, Landewe R, Behier J, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.